PH23192A - Pharmaceutical compositions having thrombolytic activity - Google Patents

Pharmaceutical compositions having thrombolytic activity

Info

Publication number
PH23192A
PH23192A PH34452A PH34452A PH23192A PH 23192 A PH23192 A PH 23192A PH 34452 A PH34452 A PH 34452A PH 34452 A PH34452 A PH 34452A PH 23192 A PH23192 A PH 23192A
Authority
PH
Philippines
Prior art keywords
pharmaceutical compositions
thrombolytic activity
plasminogen activators
type
thrombolytic
Prior art date
Application number
PH34452A
Other languages
English (en)
Inventor
Desire Jose Collen
Original Assignee
Leuven Res & Dev Vzw
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leuven Res & Dev Vzw filed Critical Leuven Res & Dev Vzw
Publication of PH23192A publication Critical patent/PH23192A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49Urokinase; Tissue plasminogen activator
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PH34452A 1985-11-11 1986-11-10 Pharmaceutical compositions having thrombolytic activity PH23192A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NL8503097A NL8503097A (nl) 1985-11-11 1985-11-11 Geneesmiddel met thrombolytische werking.

Publications (1)

Publication Number Publication Date
PH23192A true PH23192A (en) 1989-05-29

Family

ID=19846844

Family Applications (1)

Application Number Title Priority Date Filing Date
PH34452A PH23192A (en) 1985-11-11 1986-11-10 Pharmaceutical compositions having thrombolytic activity

Country Status (17)

Country Link
EP (1) EP0223192B1 (nl)
JP (1) JPH089546B2 (nl)
AT (1) ATE64532T1 (nl)
AU (1) AU586713B2 (nl)
CA (1) CA1303987C (nl)
DE (1) DE3679887D1 (nl)
DK (1) DK164640C (nl)
ES (1) ES2039194T3 (nl)
GR (1) GR3002226T3 (nl)
HU (1) HU196715B (nl)
IE (1) IE59387B1 (nl)
IL (1) IL80538A (nl)
NL (1) NL8503097A (nl)
NZ (1) NZ218231A (nl)
PH (1) PH23192A (nl)
PT (1) PT83721B (nl)
ZA (1) ZA868464B (nl)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8623823D0 (en) * 1986-10-03 1986-11-05 Sandoz Ltd Therapeutic lysis of fibrin blood clots
SE462829B (sv) * 1989-01-10 1990-09-10 Kabigen Ab Trombolytiskt aktiva kompositioner innehaallande en modifierad plasminogenaktivator av vaevnadstyp samt en normal human t-pa, streptokinas eller humant urokinas
AU635541B2 (en) * 1989-05-17 1993-03-25 Research Corporation Technologies, Inc. Method and composition for the treatment of thrombosis in a mammal
GB8919803D0 (en) * 1989-09-01 1989-10-18 Ciba Geigy Pharmaceutical compositions

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1642612A1 (de) * 1967-03-02 1971-09-09 Bayer Ag Die Verwendung von Erythrozyten zur Gewinnung bzw.Isolierung eines Plasminogen-Aktivators
NL8003402A (nl) * 1980-06-11 1982-01-04 Leuven Res & Dev Vzw Nieuwe plasminogeen-activator en farmaceutisch preparaat met trombolytische werking.
GT198302091A (es) * 1982-05-05 1984-10-25 Activador de plasminogeno de tejido humano a),b),c).
JPS5951220A (ja) * 1982-08-02 1984-03-24 Asahi Chem Ind Co Ltd 新規なプラスミノ−ゲン・アクチベ−タ−およびその製法ならびにこれを含有する薬剤
JPH0637398B2 (ja) * 1982-10-29 1994-05-18 三井東圧化学株式会社 血栓溶解剤
JPS59139323A (ja) * 1983-01-28 1984-08-10 Green Cross Corp:The ウロキナ−ゼ乾燥製剤
JPS6051119A (ja) * 1983-08-30 1985-03-22 Green Cross Corp:The ウロキナ−ゼ乾燥製剤
JPS60152421A (ja) * 1984-01-23 1985-08-10 Sanwa Kagaku Kenkyusho:Kk ヒト胎盤性プラスミノ−ゲン活性化因子、及びそれとヒトプラスミノ−ゲン活性化阻害因子との結合物、及びそれらの製法
GB8430253D0 (en) * 1984-11-30 1985-01-09 Beecham Group Plc Compounds
JPH0610139B2 (ja) * 1986-05-15 1994-02-09 エモリ ユニバーシティ 繊維素溶解性合成物混合物及び血管内の血餅溶解用薬剤
HUT47032A (en) * 1986-10-03 1989-01-30 Sandoz Ag Process for production of medical compositions dissolving blood cut

Also Published As

Publication number Publication date
AU586713B2 (en) 1989-07-20
AU6503186A (en) 1987-05-14
HUT43794A (en) 1987-12-28
IE59387B1 (en) 1994-02-23
EP0223192B1 (en) 1991-06-19
IL80538A0 (en) 1987-02-27
IE862962L (en) 1987-05-11
DK532886D0 (da) 1986-11-07
NZ218231A (en) 1988-10-28
JPH089546B2 (ja) 1996-01-31
PT83721B (pt) 1988-08-17
DE3679887D1 (de) 1991-07-25
DK532886A (da) 1987-05-12
ZA868464B (en) 1987-06-24
ES2039194T3 (es) 1993-09-16
HU196715B (en) 1989-01-30
ATE64532T1 (de) 1991-07-15
NL8503097A (nl) 1987-06-01
DK164640C (da) 1992-12-14
DK164640B (da) 1992-07-27
JPS62155222A (ja) 1987-07-10
GR3002226T3 (en) 1992-12-30
IL80538A (en) 1991-06-30
CA1303987C (en) 1992-06-23
PT83721A (en) 1986-12-01
EP0223192A1 (en) 1987-05-27

Similar Documents

Publication Publication Date Title
IL80659A (en) Modified tissue plasminogen activators,their preparation and pharmaceutical compositions containing them
ZA897173B (en) Pharmaceutically active combination
NZ216306A (en) Pharmaceutical compositions containing tissue plasminogen activator
IL78938A0 (en) Pharmaceutical composition containing tissue plasminogen activator and its preparation
ES2000743A6 (es) Estuche y procedimiento para preparar una unidad de dosificacion de activador de plasminogeno de tejidos humanos.
NZ219829A (en) Tissue-type plasminogen activator modified in the region of amino acids 67-69 and pharmaceutical compositions thereof
IL80538A0 (en) Pharmaceutical compositions having thrombolytic activity
NZ217331A (en) Tissue plasminogen activator derivatives and genetically engineered product
IL91774A0 (en) Preparation of plasminogen activator expressed in prokaryotes
EP0158880A3 (en) Liposomes with inhalable allergens for treatment of allergies, method for their preparation and pharmaceutical compositions containing them
GR3006053T3 (nl)
ZA863956B (en) Pharmaceutical formulations containing tissue plasminogen activator
ES8704903A1 (es) Un metodo para preparar 6-cloro-2-metil-1h-2,3,4,5-tetrahidro-3-benzazepen-n-oxido.
EP0300033A4 (en) PROTEASE-LIKE CYTOTOXIC LYMPHOCYTE-SPECIFIC MOLECULES AND METHOD.
NZ223291A (en) Modified tissue-type plasminogen activator
IE883342L (en) Human tissue-type plasminogen activator variant
IE860355L (en) Modified tissue-type plasminogen activator
IL109760A0 (en) Modified human tissue-type plasminogen activator which retains its biological activity and is characterized by an increased in vivo hlaf-life